HEMLIBRA®now available for patients with and without inhibitor (Hemophilia A)
On October 4, 2018, the FDA approved HEMLIBRA® for prevention (prophylaxis) of bleeding episodes in adults and children ages newborn and older with Factor VIII deficiency (Hemophilia A) without an inhibitor. In November 2017, the FDA licensed HEMLIBRA® for use in FVIII deficiency with inhibitors. HEMLIBRA® works for both patients with and without an inhibitor with FVIII deficiency (Hemophilia A)!
The IHTC has the most experience, knowledge, and expertise with HEMLIBRA® in Indiana. The IHTC staff have been extensively trained regarding how to dose, prescribe, monitor and administer HEMLIBRA®. If you have any questions or want information about HEMLIBRA®, call the center at 1-877-CLOTTER.
LEARN MORE ABOUT THE MOST RECENT FDA APPROVAL OF HEMLIBRA®